Objective. Dementia is an age-related progressive neurodegenerative disorder afflicting about 5% of the world's population, and it is expected to grow dramatically in the future keeping in view our ageing society. Currently available medications appear to be able to produce moderate symptomatic benefits but do not to stop disease progression. In this article, the management of the disorder, including the currently available drugs as well as psychosocial strategies, is discussed. Methods. A computerized search on Pubmed from 1980 to 2006 was carried out and all articles evaluated and graded on NICE guidelines. Results and conclusions. Currently evaluated and accepted medications only bring about a reduction in the deteriorating course. A combination of pharmacotherapy and psychosocial management is the need of the hour.
Neugroschl JA , Kolevzon A., Samuels SC, Marin DBDementia. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry. Philadelphia, PA: Lippincott Williams & Wilkins;2005:1068-1093.
2.
Alzheimer's Society.Demography-Policy position paper. http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=412&pageNumber=1. Published 2003. Accessed June 27, 2007.
3.
Eisai Alzheimer's Worldwide.Alzheimer's disease worldwide. http://www.eisai.co.uk/worldwide.htm . Published 2003. Accessed June 25, 2007.
4.
Brodaty H., Gresham M., Luscombe G.The Prince Henry Hospital dementia caregivers' training programme . Int J Geriatr Psychiatry. 1997;12:183-192.
5.
World Health Organization.International Classification of Diseases (ICD 10). Geneva , Switzerland: World Health Organization; 1992.
6.
American Psychiatric Association.Diagnosis and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
7.
Flicker L., LoGiudice D., Carlin JB, Ames D.The predictive value of dementia screening instruments in clinical populations . Int J Geriatr Psychiatry. 1997;12:203-209.
8.
Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153.
9.
Eastley R., Wilcock G.Assessment and differential diagnosis of dementia. In: O'Brien J, Ames D , Burns A, eds. Dementia. 2nd ed. London: Arnold ; 2000.
10.
AGS Clinical Practice Committee.Guidelines abstracted from the American Academy of Neurology's dementia guidelines for early detection, diagnosis, and management of dementia. J Am Geriatr Soc. 2003;51:869-873.
11.
Celsis P.Age related cognitive decline, mild cognitive impairment or pre clinical Alzheimer's disease. Ann Med. 2000;32:6-14.
12.
LoGiudice D.Dementia: an update to refresh your memory . Inter Med J. 2002;32:535-540.
13.
Doody RS, Stevens JC, Beck C., et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56: 1154-1166.
14.
Brodaty H., Ames D., Boundy KL, et al. Pharmacological treatment of cognitive deficits in Alzheimer's disease. Med J Aust. 2001;175:324-329.
15.
Passmore AP , Bayer AJ, Steinhagen-Thiessen E.Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. J Neurol Sci. 2005; 229:141-146.
16.
Moretti R., Torre P., Antonello RM, Cazzato G., Bava A.Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci. 2002;203:141-146.
17.
Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju CVEfficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283-1290.
18.
Wilcock G., Möbius HJ, Stöffler A.A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol . 2002;17:297-305.
19.
Jick H., Zornberg GL, Jick SS, Seshadri S., Drachman DAStatins and the risk of dementia. Lancet. 2000;356: 1627-1631.
20.
Pantoni L., del Ser T., Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke. 2005;36: 619-624.
21.
Bar KJ, Franke S., Wenda B., et al. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2003;24:333-338.
22.
Rother M., Erkinjuntti T., Roessner M., Kittner B., Marcusson J., Karlsson I.Propentofylline in the treatment of Alzheimer's disease and vascular dementia . Dement Geriatr Cogn Disord. 1998 ;9:36-43.
23.
McKeith IG, Del-Ser T., Anand R., et al. Rivastigmine provides symptomatic benefit in dementia with Lewy bodies: findings from placebo-controlled international multicenter study. Neurology. 2000;54:A450.
24.
Barber R., Pannikar A., McKeith IGDementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry. 2001;16:S12-S18.
25.
Moretti R., Torre P., Antonello RM, Cazzato G., Bava A.Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol . 2003;49:13-19.
26.
Moretti R., Torre P., Antonello RM, Cazzato G., Bava A.Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation . Int J Geriatr Psychiatry. 2002;17:391-392.
27.
Jones G., Power C.Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis. 2006;21:1-17.
28.
Brown P.Drug therapy in human and experimental transmissible spongiform encephalopathy . Neurology. 2002;58:1720-1725.
29.
Ross CA, Margolis RLHuntington's disease. Clin Neurosci Res. 2001 ;1:142-152.
30.
Jann MW, Pharm D., Small GWCholinesterase inhibitors and similarly acting compounds. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry. Philadelphia, PA: Lippincott Williams & Wilkins;2005: 2808-2817.
31.
Wilcock GK, Whitehead A., Evans JG, Birks J., Perdomo C., Pratt RDDonepezil: a meta-analysis of individual patient's data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease . Neurology. 2001;56(suppl 3):339.
32.
Rosler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. Br Med J. 1999;318:663-668.
Shua-Haim JR , Ross JSCurrent and the near future medications for Alzheimer's Disease. What can we expect from them?Am J Alzheimers Dis Other Demen. 1999;14(suppl):294-307.
35.
de Jongh P.Clinical Development of Metrifonate: An Overview of Cognitive and Global Outcomes. Collegium Internationale Neuro-Psychopharmacologium. Glasgow, Scotland: Bayer AG; 1998.
36.
Dubois B., McKeith I., Orgogozo J., Collins O., Meulien D.Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry . 1999;14:973-982.
37.
Shikiar R., Shakespeare A., Sagnier P., et al. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from MALT clinical trial. J Am Geriatr Soc. 2000;48:268-274.
38.
Becker R., Giacobini E., Elble R., McIlhany M., Sherman K.Potential pharmacotherapy of Alzheimer's disease. A comparison of various forms of physostigmine administration. Acta Neurol Scand Suppl . 1988;77:19-32.
39.
Reisberg B., Doody R., Stöffler A., Schmitt F., Ferris S., Möbius HJ; Memantine Study Group.Memantine in moderate to severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
40.
Pomara N., Peskind ER, Potkin SG, et al. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomised controlled trial. Neurobiol Aging. 2004;25(suppl 2):19.
41.
Rive B., Vercelletto M., Damier FD, Cochran J., Francois C.Memantine enhances autonomy in moderate to severe Alzheimer's disease . Int J Geriatr Psychiatry. 2004;19: 458-464.
42.
López-Arrieta, Birks J.Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2007;(1):CD000147. doi:10.1002/14651858. CD000147.
43.
Frampton M. , Harvey RJ, Kirchner V.Propentofylline for dementia. Cochrane Database Syst Rev.2003 ;(2): CD002853.doi:10.1002/14651858.CD002853.
44.
McGuire D., Marder K.Pharmacological frontiers in the treatment of AIDS dementia. J Psychopharmacol. 2000; 14:251-257.
45.
Wilkinson D.Drugs for treatment of Alzheimer's disease . Int J Clin Pract. 2001;55:129-34.
46.
Kumar R., Orgogozo J.Efficacy and safety of SB202026 as a symptomatic treatment for Alzheimer's disease. Neurobiol Aging. 1996;17:161.
47.
Olanow CWA radical hypothesis for neurodegeneration. Trends Neurosci . 1993;16:439-444.
48.
Sano M., Ernesto C., Thomas RG, et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Eng J Med. 1997;336:1216-1222.
49.
Aisen PS, Davis KLThe search for disease-modifying treatment for Alzheimer's disease . Neurology. 1997;48 (suppl):35S-41S.
50.
Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident of Alzheimer's disease in a biracial community study. JAMA . 2002;287:3230-3237.
51.
Jansen SL, Forbes DA, Duncan V., Morgan DGMelatonin for cognitive impairment. Cochrane Database Syst Rev.2006;(1):CD003802.doi:10.1002/14651858.CD003802.
52.
Fioravanti M., Flicker L.Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev.2001;(4):CD003159.doi: 10.1002/14651858.CD003159.
53.
Rogers J., Kirby LC, Hempelman SR, et al. Clinical trial on indomethacin in Alzheimer's disease. Neurology. 1993;43:1609-1611.
54.
Scharf S., Mander A., Ugoni A., Vajda F., Christophidis N.A double-blind, placebo controlled trial of diclofenac/ misoprostol in Alzheimer's disease. Neurology. 1999; 53:197-201.
55.
Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease . The Alzheimer's Disease Cooperative study. Neurology. 2000; 54:588-593.
56.
Schneider LS , Farlow MR, Pogoda JMPotential role of estrogen replacement in the treatment of Alzheimer's dementia. Am J Med.1997;103(suppl 3A):46S-50S.
57.
Nathan L., Chaudhuri G.Antioxidant and pro-oxidant actions of estrogens: potential physiological and clinical implications. Semin Reprod Endocrinol. 1998;16:309-314.
58.
Inestrosa NC , Marzolo MP, Bonnefont ABCellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease . Mol Neurobiol1998; 17:73-86.
59.
Rockwood K. , Kirkland S., Hogan DB, et al. Use of lipid lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-227.
60.
Hijjar I., Schumert J., Hirth V., Wieland D., Eleazer GPThe impact of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci. 2002;M414-M418.
61.
Fassbender K., Simons M., Bergmann C., et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001 ;98:5856-5861.
62.
Locatelli S. , Lutjohann D., Schmidt HH, Otto C., Beisiegel U., von Bergmann K.Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain . Arch Neurol . 2002;59:213-216.
63.
Scott HD, Laake K.Statins for the reduction of risk of Alzheimer's disease. Cochrane Database Syst Rev. 2001:(4): CD003160.
64.
Flaherty DB , Soria JP, Tomasiewicz HG, Wood JGPhosphorylation of human tau protein by microtubuleassociate kinase: GSK3beta and cdk5are key participants. J Neurosci Res. 2000;62:463-472.
65.
Sang H., Lu Z., Li Y., Ru B., Wang, Chen J.Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules. Neurosci Lett. 2001;312:141-144.
66.
Chen G., Huang LD, Jiang YM, Manji HKThe mood stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem. 1999;72: 1327-1330.
67.
Martinez A. , Alonso M., Castro A., Perez C., Moreno FJFirst non-ATP competitive glycogen synthase 5 beta (GSK-3 beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheirmer's disease. J Med Chem. 2002;45:1292-1299.
68.
Englels HJ, Wirth JCNo ergogenic effects of ginseng during graded maximal aerobic exercise . J Am Diet Assoc. 1997;97:1110-1115.
69.
Bai DL, Tang XC, He XCHuperzine A, a potential therapeutic agent for treatment of Alzheimer's disease . Curr Med Chem. 2000;7:355-374.
70.
Ou LY, Tang XC, Cai JXEffect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys. Eur J Pharmacol. 2001;433:151-156.
71.
Pepping J.Huperzine A.Am J Health Syst Pharm. 2000; 57:533-534.
72.
Gelinas DS, DaSilva K., Fenili D., George PS, McLaurin J.Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A. 2004;101(suppl 2):14657-14662.
73.
Paganetti P. , Calanca V., Galli C., Stefani M., Molinari M.β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide. J Cell Biol. 2005;168: 863-868.
74.
Arbel M., Yacoby I., Solomon B.Inhibitor of amyloid precursor protein processing by β-secretase through site directed antibodies. Proc Natl Acad Sci U S A . 2005;102: 7718-7723.
75.
Li Y., Wang H., Wang S., Quon D., Liu YW, Cordell B.Positive and negative regulation of APP amyloidogenesis by sumoylation . Proc Natl Acad Sci U S A. 2003;100:259-264.
76.
Verger A., Perdomo J., Crossley M.Modification with SUMO. A role in transcriptional regulation. EMBO Rep. 2003;4:137-142.
77.
Lee JY, Friedman JE, Angel L., Kozak A., Koh JYThe lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human b-amyloid precursor protein transgenic mice. Neurobiol Aging. 2004;25:1315-1321.
78.
Hsiao K., Chapman P., Nilsen S., et al. Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice. Science. 1996;274:99-102.
79.
Foxall G., Leek S., Maddock S.Cognitive antecedents of consumers' willingness to purchase fish rich in polyunsaturated fatty acids (PUFA). Appetite. 1998;31:391-402.
80.
Bates J., Boote J., Beverley C.Psychosocial interventions for people with a milder dementing illness: a systematic review. J Adv Nurs. 2004;45:644-656.
81.
Emerson E.Working with people with challenging behaviour. In: Emerson E, Hatton J, Bromley J, Caine A, eds. Clinical Psychology and People with Intellectual Disabilities . Chichester, UK: John Wiley; 1998:127-153.
82.
Burgio L., Fisher S.Application of psychosocial interventions for treating behavioural and psychological symptoms of dementia. Int Psychogeriatr . 2000 ;12(suppl 1):351-358.
83.
Woods RTPsychological Problems of Ageing. Chichester, UK: John Wiley; 1999.
84.
Bourgeois MSConversing with Memory Impaired Individuals' Aids: A Memory Aid Workbook. Bicester, UK: Winslow Press;1992 .
85.
Teri L., Gallagher-Thompson D.Cognitive-behavioural interventions for treatment of depression in Alzheimer's patients. Gerontologist. 1991;31:413-416.
86.
Kipling T., Bailey M., Charlesworth G.The feasibility of a cognitive behavioural therapy group for men with a mild/ moderate cognitive impairment. Behav Cogn Psychother . 1999;27:189-193.
87.
Baldelli MV , Pirani A., Motta M., Abati E., Mariani E., Manzi V.Effects of reality orientation therapy on elderly patients in the community. Arch Gerontol Geriatr. 1993; 17:211-218.
88.
Zanetti O., Binetti G., Magni E., Rozzini L., Bianchetti A., Trabucchi M.Procedural memory stimulation in Alzheimer's disease: impact of a training programme. Acta Neurol Scand. 1997 ;95:152-157.
89.
Spector A., Orrell M., Davies S., Woods B.Reality orientation for dementia. Cochrane Library. 2002;(3). Oxford, UK: Update Software .
90.
Kasl-Godley J., Gatz M.Psychosocial interventions for individuals with dementia: an integration of theory, therapy, and a clinical understanding of dementia. Clin Psychol Rev. 2000;6:755-782.
91.
Weiner MFPractical Psychotherapy. New York, NY: Brunner/Mazel; 1986.
92.
Feil N.Group therapy in a home for the aged. Gerontologist . 1967;7:192-195.
93.
Hitch S.Cognitive therapy as a tool for the caring elderly confused person . J Clin Nurs. 1994;3:49-55.
94.
Neal M., Briggs M.Validation therapy for dementia. Cochrane Library. 2002;(3). Oxford, UK: Update Software .
95.
Teri L., Logsdon RG, Uomoto J., McCurry SMBehavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol B Psychol Sci Soc Sci. 1997 ;52:P159-P166.
96.
Spector A., Orrell M., Davies S., Wood B.Reminiscence therapy for dementia. Cochrane Library. 2002;(3). Oxford, UK: Update Software.
97.
Gibson F.What can reminiscence contribute to people with dementia? In: Bornat J, ed. Reminiscence reviewed: Evaluations, achievements, perspectives. Buckingham, UK: Open University Press;1994:46-60.
98.
O'Donovan S.The memory lingers on. Elderly Care. 1993;5:27-31.
99.
Haight BKThe therapeutic role of a structured life-review process in homebound elderly subjects. J Gerontol. 1988;43:40-44.
100.
Buechel H.Reminiscence: a review and prospectus. Phys Occup Ther Geriatr. 1986;5:25-37.
101.
Woods P., Ashley J.Simulated presence therapy: using selected memories to manage problem behaviors in Alzheimer's disease patients. Geriatr Nurs. 1995;16:9-14.
102.
Cohen-Mansfield J., Werner P.Management of verbally disruptive behaviors in nursing home residents. J Gerontol A Biol Sci Med Sci. 1997;52:M369-M377.
103.
Snyder M., Egan EC, Burns KREfficacy of hand massage in decreasing agitation behaviors associated with care activities in persons with dementia. Geriatr Nurs . 1995;16:60-63.
104.
Churchill M., Safaoui J., McCabe B., Baun MMUsing a therapy dog to alleviate the agitation and desocialization of people with Alzheimer's disease. J Psychosoc Nurs Ment Health Serv. 1999;37:16-22.
105.
Ford M., Fox J., Fitch S., Donovan A.Light in the darkness. Nurs Times. 1987;83:26-29.
